In patients with PD-L1 negative metastatic cervical squamous cell carcinoma at primary diagnosis, do you add pembrolizumab, atezolizumab, or no immunotherapy to combination platinum/taxane/bevacizumab therapy?
The subset analysis of KEYNOTE 826 suggests no benefit in patients with CPS <1, but BEATcc included IO regardless of PD-L1 status.
Community PollStarted
In a patient with metastatic, PD-L1 negative cervical cancer at initial diagnosis, what immunotherapy do you include in their systemic therapy regimen?
37 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Answered on
You are correct that the data is not crystal clear in these patients, which means it is reasonable to consider doing either platinum/taxane/bev or platinum/taxane/bev/immunotherapy. Personally, I find that when giving all 4 agents at once, patients do experience more toxicity. So in my practice for ...
Join for free or sign in to see the full answer